U
MusclePharm Corporation
MSLPQ
$0.00
$0.000.00%
D
Sell
3/28/2023Upgraded
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 3/28/2023 due to an increase in the volatility index.
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 3/28/2023 due to an increase in the volatility index.
E
Sell
3/10/2023Downgrade
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 3/10/2023 due to a decline in the volatility index.
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 3/10/2023 due to a decline in the volatility index.
D
Sell
2/21/2023Upgraded
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 2/21/2023 due to an increase in the volatility index and total return index.
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 2/21/2023 due to an increase in the volatility index and total return index.
E
Sell
2/3/2023Downgrade
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 2/3/2023 due to a decline in the volatility index and total return index.
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 2/3/2023 due to a decline in the volatility index and total return index.
D
Sell
1/19/2023Upgraded
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 1/19/2023 due to an increase in the volatility index.
MusclePharm Corporation (MSLPQ) was upgraded to D- from E+ on 1/19/2023 due to an increase in the volatility index.
E
Sell
12/28/2022Downgrade
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 12/28/2022 due to a decline in the volatility index and total return index.
MusclePharm Corporation (MSLPQ) was downgraded to E+ from D- on 12/28/2022 due to a decline in the volatility index and total return index.
D
Sell
12/12/2022Upgraded
MusclePharm Corporation (MSLP) was upgraded to D- from E+ on 12/12/2022 due to a substantial increase in the valuation index and volatility index.
MusclePharm Corporation (MSLP) was upgraded to D- from E+ on 12/12/2022 due to a substantial increase in the valuation index and volatility index.
E
Sell
11/25/2022Downgrade
MusclePharm Corporation (MSLP) was downgraded to E+ from D- on 11/25/2022 due to a decline in the volatility index and total return index.
MusclePharm Corporation (MSLP) was downgraded to E+ from D- on 11/25/2022 due to a decline in the volatility index and total return index.
D
Sell
5/17/2022Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 5/17/2022 due to a decline in the total return index and solvency index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 5/17/2022 due to a decline in the total return index and solvency index.
D
Sell
5/5/2022Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 4/20/2022 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 72.29% from -$3.93M to -$6.78M.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 4/20/2022 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 72.29% from -$3.93M to -$6.78M.
D
Sell
9/28/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to D from D+ on 9/28/2021 due to a major decline in the total return index.
MusclePharm Corporation (MSLP) was downgraded to D from D+ on 9/28/2021 due to a major decline in the total return index.
D
Sell
9/10/2021Upgraded
MusclePharm Corporation (MSLP) was upgraded to D+ from D on 9/10/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
MusclePharm Corporation (MSLP) was upgraded to D+ from D on 9/10/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
8/20/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to D from D+ on 8/20/2021 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0021 to -$0.0674, net income declined 2,494.68% from $94 to -$2.25M, and operating cash flow declined 1,117.35% from $98 to -$997.
MusclePharm Corporation (MSLP) was downgraded to D from D+ on 8/20/2021 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0021 to -$0.0674, net income declined 2,494.68% from $94 to -$2.25M, and operating cash flow declined 1,117.35% from $98 to -$997.
D
Sell
8/18/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to D+ from C- on 8/18/2021 due to a substantial decline in the total return index.
MusclePharm Corporation (MSLP) was downgraded to D+ from C- on 8/18/2021 due to a substantial decline in the total return index.
C
Hold
8/16/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to C- from C on 8/16/2021 due to a large decline in the total return index.
MusclePharm Corporation (MSLP) was downgraded to C- from C on 8/16/2021 due to a large decline in the total return index.
C
Hold
7/30/2021Upgraded
MusclePharm Corporation (MSLP) was upgraded to C from C- on 7/30/2021 due to a major increase in the total return index, valuation index and volatility index.
MusclePharm Corporation (MSLP) was upgraded to C from C- on 7/30/2021 due to a major increase in the total return index, valuation index and volatility index.
C
Hold
6/24/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to C- from C on 6/24/2021 due to a noticeable decline in the total return index and valuation index.
MusclePharm Corporation (MSLP) was downgraded to C- from C on 6/24/2021 due to a noticeable decline in the total return index and valuation index.
C
Hold
6/9/2021Upgraded
MusclePharm Corporation (MSLP) was upgraded to C from C- on 6/9/2021 due to a large increase in the total return index.
MusclePharm Corporation (MSLP) was upgraded to C from C- on 6/9/2021 due to a large increase in the total return index.
C
Hold
5/25/2021Downgrade
MusclePharm Corporation (MSLP) was downgraded to C- from C on 5/25/2021 due to a substantial decline in the efficiency index, valuation index and growth index. Earnings per share declined from $0.085 to $0.0021, net income declined 96.67% from $2.82M to $94, and EBIT declined 74.46% from $1.07M to $272.
MusclePharm Corporation (MSLP) was downgraded to C- from C on 5/25/2021 due to a substantial decline in the efficiency index, valuation index and growth index. Earnings per share declined from $0.085 to $0.0021, net income declined 96.67% from $2.82M to $94, and EBIT declined 74.46% from $1.07M to $272.
C
Hold
3/30/2021Upgraded
MusclePharm Corporation (MSLP) was upgraded to C from D on 3/30/2021 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 315.93% from $678 to $2.82M, and total capital increased 35.92% from -$20.26M to -$12.98M.
MusclePharm Corporation (MSLP) was upgraded to C from D on 3/30/2021 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 315.93% from $678 to $2.82M, and total capital increased 35.92% from -$20.26M to -$12.98M.
D
Sell
11/27/2020Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 11/27/2020 due to a substantial increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0077 to $0.01, EBIT increased 129.43% from $350 to $803, and operating cash flow increased 33.88% from $1.03M to $1.38M.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 11/27/2020 due to a substantial increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0077 to $0.01, EBIT increased 129.43% from $350 to $803, and operating cash flow increased 33.88% from $1.03M to $1.38M.
D
Sell
11/16/2020Upgraded
MusclePharm Corporation (MSLP) was upgraded to D- from E+ on 11/16/2020 due to an increase in the volatility index and total return index.
MusclePharm Corporation (MSLP) was upgraded to D- from E+ on 11/16/2020 due to an increase in the volatility index and total return index.
E
Sell
10/30/2020Downgrade
MusclePharm Corporation (MSLP) was downgraded to E+ from D- on 10/30/2020 due to a significant decline in the solvency index, growth index and total return index. Operating cash flow declined 308.56% from $1.1M to -$2.29M, total revenue declined 17.74% from $21.18M to $17.42M, and the quick ratio declined from 0.16 to 0.15.
MusclePharm Corporation (MSLP) was downgraded to E+ from D- on 10/30/2020 due to a significant decline in the solvency index, growth index and total return index. Operating cash flow declined 308.56% from $1.1M to -$2.29M, total revenue declined 17.74% from $21.18M to $17.42M, and the quick ratio declined from 0.16 to 0.15.
D
Sell
12/26/2019Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 12/26/2019 due to a decline in the total return index and volatility index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 12/26/2019 due to a decline in the total return index and volatility index.
D
Sell
12/11/2019Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 12/11/2019 due to an increase in the volatility index and total return index.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 12/11/2019 due to an increase in the volatility index and total return index.
D
Sell
11/26/2019Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 11/26/2019 due to a decline in the volatility index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 11/26/2019 due to a decline in the volatility index.
D
Sell
10/11/2019Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 10/11/2019 due to an increase in the total return index.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 10/11/2019 due to an increase in the total return index.
D
Sell
8/22/2019Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 8/22/2019 due to a decline in the volatility index and total return index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 8/22/2019 due to a decline in the volatility index and total return index.
D
Sell
8/7/2019Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 8/7/2019 due to an increase in the volatility index.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 8/7/2019 due to an increase in the volatility index.
D
Sell
2/15/2019Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 2/15/2019 due to a decline in the total return index and volatility index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 2/15/2019 due to a decline in the total return index and volatility index.
D
Sell
11/19/2018Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 11/19/2018 due to an increase in the growth index and total return index. Operating cash flow increased 968.39% from $193 to $2.06M, EBIT increased 90.54% from -$2.62M to -$248, and total revenue increased 1.05% from $27.1M to $27.39M.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 11/19/2018 due to an increase in the growth index and total return index. Operating cash flow increased 968.39% from $193 to $2.06M, EBIT increased 90.54% from -$2.62M to -$248, and total revenue increased 1.05% from $27.1M to $27.39M.
D
Sell
8/24/2018Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 8/24/2018 due to a noticeable decline in the efficiency index. Total capital declined 35.93% from $10.06M to $6.45M.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 8/24/2018 due to a noticeable decline in the efficiency index. Total capital declined 35.93% from $10.06M to $6.45M.
D
Sell
7/27/2018Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 7/27/2018 due to an increase in the total return index, volatility index and solvency index.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 7/27/2018 due to an increase in the total return index, volatility index and solvency index.
D
Sell
11/15/2017Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 11/15/2017 due to a noticeable decline in the efficiency index, total return index and volatility index.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 11/15/2017 due to a noticeable decline in the efficiency index, total return index and volatility index.
D
Sell
8/16/2017Upgraded
MusclePharm Corporation (MSLP) was upgraded to D from D- on 8/16/2017 due to a substantial increase in the valuation index, efficiency index and growth index. EBIT increased 63.27% from -$2.59M to -$952, operating cash flow increased 25.62% from -$1.04M to -$775, and total capital increased 2.72% from $11.45M to $11.76M.
MusclePharm Corporation (MSLP) was upgraded to D from D- on 8/16/2017 due to a substantial increase in the valuation index, efficiency index and growth index. EBIT increased 63.27% from -$2.59M to -$952, operating cash flow increased 25.62% from -$1.04M to -$775, and total capital increased 2.72% from $11.45M to $11.76M.
D
Sell
5/19/2017Downgrade
MusclePharm Corporation (MSLP) was downgraded to D- from D on 5/19/2017 due to a significant decline in the solvency index and growth index. EBIT declined 141.34% from -$1.07M to -$2.59M, earnings per share declined from $0.7253 to -$0.2286, and debt to equity increased from -3.92 to -2.51.
MusclePharm Corporation (MSLP) was downgraded to D- from D on 5/19/2017 due to a significant decline in the solvency index and growth index. EBIT declined 141.34% from -$1.07M to -$2.59M, earnings per share declined from $0.7253 to -$0.2286, and debt to equity increased from -3.92 to -2.51.
D
Sell
5/11/2016Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to D from D- on 5/11/2016 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 206.9% from -$2.22M to $2.37M, earnings per share increased from -$0.6988 to -$0.4753, and total revenue increased 4.46% from $41.08M to $42.91M.
Muscle Pharm Corp. (MSLP) was upgraded to D from D- on 5/11/2016 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 206.9% from -$2.22M to $2.37M, earnings per share increased from -$0.6988 to -$0.4753, and total revenue increased 4.46% from $41.08M to $42.91M.
D
Sell
3/11/2016Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Muscle Pharm Corp. (MSLP) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
D
Sell
1/12/2016Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index and volatility index.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index and volatility index.
D
Sell
12/28/2015Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 12/28/2015 due to an increase in the total return index, valuation index and volatility index.
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 12/28/2015 due to an increase in the total return index, valuation index and volatility index.
D
Sell
5/11/2015Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 5/11/2015 due to a major decline in the total return index, efficiency index and growth index. Earnings per share declined from -$1.3916 to -$0.5609, EBIT declined 55.58% from -$16.4M to -$7.28M, and net income declined 53.94% from -$16.24M to -$7.48M.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 5/11/2015 due to a major decline in the total return index, efficiency index and growth index. Earnings per share declined from -$1.3916 to -$0.5609, EBIT declined 55.58% from -$16.4M to -$7.28M, and net income declined 53.94% from -$16.24M to -$7.48M.
D
Sell
3/20/2015Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D+ from C- on 3/20/2015 due to a significant decline in the efficiency index, solvency index and volatility index. Net income declined 2,794.37% from $602.6 to -$16.24M, debt to equity increased from 0.21 to 0.34, and total capital declined 31.91% from $46.37M to $31.57M.
Muscle Pharm Corp. (MSLP) was downgraded to D+ from C- on 3/20/2015 due to a significant decline in the efficiency index, solvency index and volatility index. Net income declined 2,794.37% from $602.6 to -$16.24M, debt to equity increased from 0.21 to 0.34, and total capital declined 31.91% from $46.37M to $31.57M.
C
Hold
12/15/2014Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to C- from C on 12/15/2014 due to a significant decline in the volatility index and total return index.
Muscle Pharm Corp. (MSLP) was downgraded to C- from C on 12/15/2014 due to a significant decline in the volatility index and total return index.
C
Hold
11/21/2014Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to C from D on 11/21/2014 due to a significant increase in the efficiency index. Total capital increased 25.35% from $36.99M to $46.37M.
Muscle Pharm Corp. (MSLP) was upgraded to C from D on 11/21/2014 due to a significant increase in the efficiency index. Total capital increased 25.35% from $36.99M to $46.37M.
D
Sell
11/19/2014Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 11/19/2014 due to a decline in the total return index, efficiency index and growth index.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 11/19/2014 due to a decline in the total return index, efficiency index and growth index.
D
Sell
11/4/2014Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 11/4/2014 due to an increase in the valuation index.
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 11/4/2014 due to an increase in the valuation index.
D
Sell
10/13/2014Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 10/13/2014 due to a decline in the valuation index and volatility index.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 10/13/2014 due to a decline in the valuation index and volatility index.
D
Sell
9/26/2014Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 9/26/2014 due to a noticeable increase in the total return index and valuation index.
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 9/26/2014 due to a noticeable increase in the total return index and valuation index.
D
Sell
9/5/2014Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 9/5/2014 due to a decline in the valuation index and volatility index.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 9/5/2014 due to a decline in the valuation index and volatility index.
D
Sell
8/8/2014Upgraded
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 8/8/2014 due to a significant increase in the volatility index, growth index and total return index.
Muscle Pharm Corp. (MSLP) was upgraded to D+ from D on 8/8/2014 due to a significant increase in the volatility index, growth index and total return index.
D
Sell
5/6/2014Downgrade
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 5/6/2014 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 168.61% from -$3.99M to $2.74M.
Muscle Pharm Corp. (MSLP) was downgraded to D from D+ on 5/6/2014 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 168.61% from -$3.99M to $2.74M.
D
Sell
4/1/2014Downgrade
Muscle Pharm Corp. (MSLPD) was downgraded to D+ from C- on 4/1/2014 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 33.1% from -$2.88M to -$1.93M, and earnings per share declined from -$0.4656 to -$0.4483.
Muscle Pharm Corp. (MSLPD) was downgraded to D+ from C- on 4/1/2014 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 33.1% from -$2.88M to -$1.93M, and earnings per share declined from -$0.4656 to -$0.4483.
OTC PK
03/05/2025 3:55PM Eastern
Quotes delayed
